The Lipid Droplet as a Potential Therapeutic Target in NAFLD

被引:43
|
作者
Goh, Vera J. [1 ]
Silver, David L. [1 ]
机构
[1] Duke NUS Grad Med Sch, Signature Res Program Cardiovasc & Metab Disorder, Singapore 169857, Singapore
基金
英国医学研究理事会;
关键词
nonalcoholic fatty liver disease; lipid droplets; triglyceride; FATTY LIVER-DISEASE; SEIP CONGENITAL LIPODYSTROPHY; TRIGLYCERIDE TRANSFER PROTEIN; PPAR-GAMMA; ENDOPLASMIC-RETICULUM; INSULIN-RESISTANCE; HEPATIC STEATOSIS; APOLIPOPROTEIN-B; PHOSPHATIDYLCHOLINE SYNTHESIS; TRIACYLGLYCEROL SYNTHESIS;
D O I
10.1055/s-0033-1358521
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic fatty liver disease (NAFLD) is a growing problem worldwide. Nonalcoholic fatty liver disease is characterized by an abnormal accumulation of triglyceride-rich lipid droplets (LDs) in the liver, which can lead to liver inflammation and metabolic disturbances. Lipid droplets are dynamic organelles that have recently gained considerable scientific interest. Their formation and growth are regulated processes requiring the participation of many endoplasmic reticulum- (ER-) and LD-associated proteins, which may serve as potential therapeutic targets for NAFLD. Protein families such as fat-inducing transmembrane proteins 1 and 2 (FITM1/FIT1 and FITM2/FIT2), the CIDE family of proteins, and the perilipin family, play important roles in LD biology. In this review, the authors discuss current views on LD formation and growth, and how various proteins may affect LD metabolism and lipoprotein assembly in the pathogenesis of NAFLD.
引用
收藏
页码:312 / 320
页数:9
相关论文
共 50 条
  • [1] The CBS/CSE system: a potential therapeutic target in NAFLD?
    Sarna, Lindsei K.
    Siow, Yaw L.
    Karmin, O.
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2015, 93 (01) : 1 - 11
  • [2] Impact of NAFLD and its pharmacotherapy on lipid profile and CVD
    Wang, Zhenya
    Ye, Mao
    Zhang, Xiao-Jing
    Zhang, Peng
    Cai, Jingjing
    Li, Hongliang
    She, Zhi-Gang
    ATHEROSCLEROSIS, 2022, 355 : 30 - 44
  • [3] Comprehensive Analysis of NAFLD and the Therapeutic Target Identified
    Wen, Weiheng
    Wu, Peili
    Zhang, Yugang
    Chen, Zijian
    Sun, Jia
    Chen, Hong
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 09
  • [4] Exercise regulation of hepatic lipid droplet metabolism
    Pino-de la Fuente, Francisco
    Carlos Borquez, Juan
    Diaz-Castro, Francisco
    Espinosa, Alejandra
    Chiong, Mario
    Troncoso, Rodrigo
    LIFE SCIENCES, 2022, 298
  • [5] Lipid Droplet Biogenesis
    Walther, Tobias C.
    Chung, Jeeyun
    Farese, Robert V., Jr.
    ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 33, 2017, 33 : 491 - 510
  • [6] HSD17B13: A Potential Therapeutic Target for NAFLD
    Zhang, Hai-bo
    Su, Wen
    Xu, Hu
    Zhang, Xiao-yan
    Guan, You-fei
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 8
  • [7] The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD
    Huang, Weifang
    Kong, Desong
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 135
  • [8] Roles of PPARs in NAFLD: Potential therapeutic targets
    Tailleux, Anne
    Wouters, Kristiaan
    Staels, Bart
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2012, 1821 (05): : 809 - 818
  • [9] A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis
    Wallstab, Christin
    Eleftheriadou, Dimitra
    Schulz, Theresa
    Damm, Georg
    Seehofer, Daniel
    Borlak, Juergen
    Holzhuetter, Hermann-Georg
    Berndt, Nikolaus
    FEBS JOURNAL, 2017, 284 (19) : 3245 - 3261
  • [10] Moderate Treadmill Exercise Alleviates NAFLD by Regulating the Biogenesis and Autophagy of Lipid Droplet
    Yang, Yangjun
    Li, Xi
    Liu, Zonghan
    Ruan, Xinyu
    Wang, Huihui
    Zhang, Qiang
    Cao, Lu
    Song, Luchen
    Chen, Yinghong
    Sun, Yi
    NUTRIENTS, 2022, 14 (22)